Access this Article


BACKGROUND: Neoadjuvant chemotherapy—often using docetaxel in various combinatorial regimens—is a standard treatment choice for advanced oesophageal squamous cell carcinoma (ESCC) in Japan. However, no useful markers exist that predict docetaxel's effects on ESCC. RPN2 silencing, which reduces glycosylation of P-glycoproteins and decreases membrane localization, promotes docetaxel-dependent apoptosis. We investigated whether RPN2 expression in ESCC biopsy specimens could be a predictive biomarker in docetaxel-based neoadjuvant chemotherapy. METHODS: We evaluated RPN2 expression immunohistochemically in biopsy specimens from 79 patients with node-positive ESCC who received docetaxel-based adjuvant chemotherapy, and compared clinical and pathologic responses between the RPN2 positive and RPN2 negative groups. We also studied susceptibility of RPN2 suppressed ESCC cells to docetaxel.RESULTS: The RPN2 negative group had better clinical and pathologic responses to docetaxel than the RPN2 positive group. We also found RPN2 suppression to alter docetaxel susceptibility in vitro. CONCLUSION: RPN2 expression in biopsy specimens could be a useful predictive marker for response to docetaxel-based neoadjuvant chemotherapy in ESCC.


  • British Journal of Cancer

    British Journal of Cancer 107(8), 1233-1238, 2012-10

    Nature Publishing Group


  • NII Article ID (NAID)
  • Text Lang
  • Article Type
  • ISSN
  • Data Source
Page Top